Results 91 to 100 of about 1,925 (192)

180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial [PDF]

Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalisations in infants worldwide. The primary analyses of HARMONIE showed that nirsevimab reduced infant hospitalisations due to RSV-associated
Drysdale, Simon B., Flamein, Florence, Knuf, Markus, Cathie, Katrina, Collins, Andrea M., Munro, Alasdair P.S., Pinquier, Didier, Carreno, Mariana, Roberts, Michelle, Moreau, Catherine, Bourron, Pierre, Cohen, Robert, Hill, Helen C., Marcelon, Lydie, HARMONIE Study Group, Kaiser, Friedrich, Faust, Saul N., Tissières, Pierre, Mari, Karine, Vassilouthis, Natalya C., Royal, Simon   +20 more
core   +1 more source

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study

Frontiers in Public Health
IntroductionRespiratory syncytial virus (RSV) infection is one of the main causes of morbidity and mortality from lower respiratory tract infections in children under 5 years of age worldwide.
José Francisco Barbas Del Buey, José Francisco Barbas Del Buey, Jesús Íñigo Martínez, María Ángeles Gutiérrez Rodríguez, Marcos Alonso García, Amaya Sánchez-Gómez, María Dolores Lasheras Carbajo, Susana Jiménez Bueno, María Dolores Esteban Vasallo, María Alejandra López Zambrano, Cristina Calvo Rey, Cristina Calvo Rey, Cristina Calvo Rey, Manuel Sanchez Luna, Manuel Sanchez Luna, Marta Molina Olivas, María Araceli Arce Arnáez   +16 more
doaj   +1 more source

Effects of Nirsevimab Introduction on Bronchiolitis and Respiratory Syncytial Virus in Catalonia

The respiratory syncytial virus (RSV) causes 70% of bronchiolitis cases and thousands of annual deaths, particularly in the paediatric population under six months, placing a significant burden on the public health system.
Valette Hohn, Berta
core   +1 more source

Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season

Eurosurveillance
Background Respiratory syncytial virus (RSV) causes substantial morbidity in infants 
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

The Efficacy and Safety of Nirsevimab in the Prevention of RSV Related Infections in Healthy Infants

Objective: To assess the efficacy and safety of preventing Respiratory Syncytial virus (RSV) related respiratory illnesses and hospitalization with the use of Nirsevimab, as compared to placebo among infants among healthy early and late preterm infants ...
Mayo, Gabrielle, Ballard, Suyin
core   +1 more source

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) poses a significant health burden on infants, particularly during their first RSV season. Immunoprophylactic strategies, such as the administration of nirsevimab, a long-acting monoclonal antibody, have been
Mersha Chetty, Paul Costello, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +4 more
doaj   +1 more source

Nirsevimab and other strategies for the prevention of RSV infection

Anales de Pediatría (English Edition), 2023
Antonio, Iofrío de Arce, Francisco José, Álvarez García   +1 more
openaire   +2 more sources

Nirsevimab som skydd mot Respiratorisk syncytialvirus (RSV) hos spädbarn : Hur effektivt och säkert är nirsevimab som skydd mot RSV hos friska spädbarn?

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among children and represents a major global health concern. Most RSV cases occur during the RSV season, which is during the cold seasons of the year. The infection often begins as
Awad, Zainab
core  

Impact of Nirsevimab immunoprophylaxis on professional exhaustion during two epidemics of respiratory syncytial virus

Objective: We aimed to assess the impact of introducing immunoprophylaxis against respiratory syncytial virus in infants (healthy infants up to 6 months of age and vulnerable children up to 24 months) on the professional quality of life of pediatric ...
Castillo-Corullón, Silvia, Calderón Garrido, Caterina, Fullana-Tur, Maravillas, Iniesta-González, Sergio, Ferrando-Monleón, Susana, Ventura-Navarro, Ana, Arcos Machancoses, José Vicente, Barrés-Fernández, Ana   +7 more
core   +1 more source